CDK4/6 and PARP inhibitors: Palbociclib and Olaparib

Mechanism

Pharmacological Class and Group

Oral targeted synthetic small molecules; selective inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6: Palbociclib) and inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP: Olaparib).

Mechanism of Action

• Palbociclib: Reversibly inhibits the kinases CDK4 and CDK6, blocking their coupling with Cyclin D. This prevents the phosphorylation of the tumor suppressor protein Retinoblastoma (Rb). Since the Rb protein is hypophosphorylated, it remains tightly bound to the mitogenic transcription factor E2F, preventing its nuclear translocation. As a result, cellular progression from the G1 phase to the S phase of the cell cycle is persistently arrested, inducing a metabolic arrest of tumor senescence.
• Olaparib: Potently inhibits the enzymes PARP-1 and PARP-2, which coordinate the repair of DNA single-strand breaks through the base excision repair pathway. The drug physically traps the enzymes at the damaged sites of the DNA, blocking the replication fork in S phase and converting single-strand breaks into double double-strand breaks that cannot be sealed in cells with inherited homologous recombination deficiency (mutation of the BRCA1 or BRCA2 genes), triggering synthetic lethality.

The Concept of Synthetic Lethality of Olaparib

Synthetic lethality describes a futility model of cell viability where the simultaneous loss of two compensatory repair pathways terminally leads to cell apoptosis:

PARP blockade (MTX BER) + BRCA1/2 mutation (MTX HR) Accumulated Double Strand Breaks Apoptosis

Normal cells retaining a wild-type allele of BRCA1/2 can safely resolve double-strand breaks forced by olaparib via the high-fidelity homologous recombination pathway, surviving therapy without structural lethal cell toxicity, providing a therapeutic window of oncological selectivity.

Pharmacokinetics

High Resolution Pharmacokinetics

• Oral absorption and Bioavailability: Rapid absorption orally. The absorption of palbociclib is increased if it is administered with food to homogenize gastric pH. Olaparib is completely absorbed and is dosed as tablets twice daily.
• Metabolism: They undergo extensive phase I hepatic metabolism mediated predominantly by the CYP3A4 isoenzyme. They do not have significant direct renal clearance.
• Elimination: They are mainly excreted fecally through biliary clearance following first-pass metabolism.
• Half-life (t_1/2): The elimination half-life is approximately 29 hours for palbociclib, facilitating a single daily dose; that of olaparib is approximately 12 to 15 hours.

Indicators and dose

Clinical Indications and Frequent Regimens

• Palbociclib: Advanced or metastatic breast cancer with positive hormone receptors (RH+) and negative human epidermal growth factor receptor 2 (HER2-), combined synergistically with an aromatase inhibitor (Letrozole) as first line or Fulvestrant in second line.
• Olaparib: Advanced high-grade epithelial ovarian cancer with confirmed germline or somatic mutation of the BRCA1 or BRCA2 genes for maintenance after complete response to platinum, HER2- metastatic breast cancer with germline BRCA mutation pretreated with anthracyclines and platinum.

Dosage and Clinical Adjustment

• Oral palbociclib: 125 mg orally once daily for 21 consecutive days, followed by 7 days of complete rest (28-day cycle).
• Oral Olaparib: 300 mg orally twice a day (total 600 mg daily) continuously.
• Clinical Adjustments: For palbociclib, if there is persistent grade 3 or grade 4 neutropenia, interrupt until recovery to grade 1 and reduce initial dose to 100 mg/day. For olaparib, if there is persistent severe grade 3 anemia, suspend until analytical recovery and reduce dose to 250 mg twice daily; rule out myelodysplasia if the condition persists.

Security

Absolute and Relative Contraindications

Contraindications of Palbociclib

• Hypersensitivity to the active ingredient.
• Severe renal dysfunction (Cl_Cr < 15 mL/min).
• Pregnancy and breastfeeding.

Olaparib contraindications

• Confirmed absence of BRCA tumor or germline mutation or homologous recombination genomic instability status.
• Concomitant use of strong inducers or inhibitors of the CYP3A4 enzyme.

Adverse Effects (ADR) and Specific Toxicity

• Palbociclib: Deep neutropenia with a reversible course in more than 80% of treated patients. Unlike chemotherapy, it does not persistently damage the cellular stroma of the marrow, and the rate of clinical febrile neutropenia is less than 1-2%. It is associated with severe fatigue and mild transient alopecia.
• Olaparib: Dose-limiting deep macrocytic anemia, mild thrombocytopenia, persistent nausea, acid dyspepsia, extreme fatigue, risk of development of Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia in less than 1-2% of platinum-pretreated patients.